{
    "clinical_study": {
        "@rank": "130997", 
        "arm_group": [
            {
                "arm_group_label": "CP-690,550 100 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Moxifloxacin hydrochloride", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "ICH E14 recommends that a thorough QT/QTc (TQT) study should be performed to determine\n      whether intensive monitoring of QT interval in target patient populations is required during\n      later stages of development.  The current study is designed to ascertain whether CP-690,550\n      is associated with QTc prolongation."
        }, 
        "brief_title": "CP-690,550 Thorough QTc Study", 
        "completion_date": {
            "#text": "February 2008", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "The current study is designed to ascertain whether CP-690,550 is associated with QTc\n      prolongation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and/or female subjects between ages of 18 and 55 years, inclusive.\n\n          -  Body Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body weight >50 kg\n             (110 lbs).\n\n        Exclusion Criteria:\n\n          -  Use of tobacco- or nicotine-containing products in excess of equivalent of 5\n             cigarettes per day.\n\n          -  12-lead ECG demonstrating QTc >450 msec or other clinically significant abnormalities\n             at Screening.\n\n          -  History of risk factors for QT prolongation or torsades de pointes.\n\n          -  Pregnant or nursing women; women of childbearing potential unwilling or unable to use\n             an acceptable method of nonhormonal contraception from at least 14 days prior to\n             first dose until completion of follow-up.\n\n          -  Use of prescription or nonprescription drugs, vitamins and dietary supplements within\n             7 days or 5 half-lives (whichever is longer) prior to first dose of trial medication.\n\n          -  Any clinically significant infections within past 3 months or evidence of infection\n             in past 7 days."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01743677", 
            "org_study_id": "A3921028"
        }, 
        "intervention": [
            {
                "arm_group_label": "CP-690,550 100 mg", 
                "description": "Single dose 100 mg (5 x 20 mg tablets)", 
                "intervention_name": "CP-690,550", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Single dose placebo tablets (5 tablets)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Moxifloxacin hydrochloride", 
                "description": "Single dose Avelox 400 mg tablet", 
                "intervention_name": "Moxifloxacin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Moxifloxacin", 
                "Norgestimate, ethinyl estradiol drug combination"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "TQT study", 
            "CP-690,550"
        ], 
        "lastchanged_date": "December 4, 2012", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921028&StudyName=CP-690%2C550%20Thorough%20QTc%20Study%20"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bruxelles", 
                        "country": "Belgium", 
                        "zip": "1070"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore", 
                        "zip": "188770"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Singapore"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1, Randomized, Placebo- And Positive-Controlled Crossover Study To Determine The Effect Of Single-Dose CP-690,550 On QTc Interval In Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Time-matched mean differences in QTcF intervals between CP-690,550 and placebo (baseline-adjusted) at each postdose time", 
                "safety_issue": "Yes", 
                "time_frame": "0.25 hr postdose"
            }, 
            {
                "measure": "Time-matched mean differences in QTcF intervals between CP-690,550 and placebo (baseline-adjusted) at each postdose time", 
                "safety_issue": "Yes", 
                "time_frame": "0.5 hr postdose"
            }, 
            {
                "measure": "Time-matched mean differences in QTcF intervals between CP-690,550 and placebo (baseline-adjusted) at each postdose time", 
                "safety_issue": "Yes", 
                "time_frame": "1 hr postdose"
            }, 
            {
                "measure": "Time-matched mean differences in QTcF intervals between CP-690,550 and placebo (baseline-adjusted) at each postdose time", 
                "safety_issue": "Yes", 
                "time_frame": "2 hr postdose"
            }, 
            {
                "measure": "Time-matched mean differences in QTcF intervals between CP-690,550 and placebo (baseline-adjusted) at each postdose time", 
                "safety_issue": "Yes", 
                "time_frame": "4 hr postdose"
            }, 
            {
                "measure": "Time-matched mean differences in QTcF intervals between CP-690,550 and placebo (baseline-adjusted) at each postdose time", 
                "safety_issue": "Yes", 
                "time_frame": "8 hr postdose"
            }, 
            {
                "measure": "Time-matched mean differences in QTcF intervals between CP-690,550 and placebo (baseline-adjusted) at each postdose time", 
                "safety_issue": "Yes", 
                "time_frame": "12 hr postdose"
            }, 
            {
                "measure": "Time-matched mean differences in QTcF intervals between CP-690,550 and placebo (baseline-adjusted) at each postdose time", 
                "safety_issue": "Yes", 
                "time_frame": "16 hr postdose"
            }, 
            {
                "measure": "Time-matched mean differences in QTcF intervals between CP-690,550 and placebo (baseline-adjusted) at each postdose time", 
                "safety_issue": "Yes", 
                "time_frame": "24 hr postdose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01743677"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean Time-Matched Difference in QTcF Intervals Between Moxifloxacin Compared to Placebo", 
                "safety_issue": "Yes", 
                "time_frame": "-1, -0.5, and 0 hrs predose and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hr postdose"
            }, 
            {
                "measure": "Mean Time-Matched Difference in QTcB Intervals Between CP-690,550 Compared to Placebo", 
                "safety_issue": "Yes", 
                "time_frame": "-1, -0.5, and 0 hrs predose and 0.25, 0.5, 1, 2, 4, 8, 12, 16 and 24 hr postdose"
            }, 
            {
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC(0-infinity)]", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.25,0.5,1,2,4,8,12,16 and 24 hr postdose"
            }, 
            {
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.25,0.5,1,2,4,8,12,16 and 24 hr postdose"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.25,0.5,1,2,4,8,12,16 and 24 hr postdose"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.25,0.5,1,2,4,8,12,16 and 24 hr postdose"
            }, 
            {
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.25,0.5,1,2,4,8,12,16 and 24 hr postdose"
            }, 
            {
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC(0-infinity)] by CYP2C19 Genotype", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.25,0.5,1,2,4,8,12,16 and 24 hr postdose"
            }, 
            {
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) by CYP2C19 Genotype", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.25,0.5,1,2,4,8,12,16 and 24 hr postdose"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax) by CYP2C19 Genotype", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.25,0.5,1,2,4,8,12,16 and 24 hr postdose"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax) by CYP2C19 Genotype", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.25,0.5,1,2,4,8,12,16 and 24 hr postdose"
            }, 
            {
                "measure": "Plasma Decay Half-Life (t1/2) by CYP2C19 Genotype", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.25,0.5,1,2,4,8,12,16 and 24 hr postdose"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2007", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}